Perspective Therapeutics Secures Orphan Drug Status in Europe for Lead Radiopharmaceutical — Perspective Therapeutics, Inc.

Event summary

Perspective Therapeutics received European orphan medicinal product designation for [²¹²Pb]VMT-α-NET in treating GEP-NETs on July 28, 2026.
[²¹²Pb]VMT-α-NET is currently being evaluated in an ongoing Phase 1/2a study (NCT05636618) for SSTR2-positive neuroendocrine tumors.
Interim clinical data presented at the 2026 ASCO Annual Meeting support [²¹²Pb]VMT-α-NET’s potential to provide significant benefit relative to approved therapies.
The designation provides development and commercial incentives, including protocol assistance, fee reductions, and up to 10 years of market exclusivity if approved.

The big picture

Perspective Therapeutics’ orphan drug designation for [²¹²Pb]VMT-α-NET underscores the growing focus on targeted radiopharmaceuticals for rare cancers. The designation not only provides critical development incentives but also highlights the unmet needs in treating GEP-NETs, a niche but expanding market driven by improved diagnostics and disease awareness. This strategic win positions Perspective Therapeutics to compete more effectively against established players in the radiopharmaceutical space.

What we're watching

Clinical Data Progress: How the pending efficacy data from Cohorts 3 and 4 will impact [²¹²Pb]VMT-α-NET’s development trajectory.
Regulatory Pathway: Whether the European orphan designation will accelerate approval timelines compared to other regions.
Commercial Strategy: The pace at which Perspective Therapeutics can leverage the market exclusivity incentives to establish [²¹²Pb]VMT-α-NET in Europe.